| Literature DB >> 35806306 |
Francesca Veronesi1, Francesca Salamanna1, Lucia Martini1, Milena Fini1.
Abstract
To date, several in vivo models have been used to reproduce the onset and monitor the progression of osteoarthritis (OA), and guinea pigs represent a standard model for studying naturally occurring, age-related OA. This systematic review aims to characterize the guinea pig for its employment in in vivo, naturally occurring OA studies and for the evaluation of specific disease-modifying agents. The search was performed in PubMed, Scopus, and Web of Knowledge in the last 10 years. Of the 233 records screened, 49 studies were included. Results showed that within a relatively short period of time, this model develops specific OA aspects, including cartilage degeneration, marginal osteophytes formation, and subchondral bone alterations. Disease severity increases with age, beginning at 3 months with mild OA and reaching moderate-severe OA at 18 months. Among the different strains, Dunkin Hartley develops OA at a relatively early age. Thus, disease-modifying agents have mainly been evaluated for this strain. As summarized herein, spontaneous development of OA in guinea pigs represents an excellent model for studying disease pathogenesis and for evaluating therapeutic interventions. In an ongoing effort at standardization, a detailed characterization of specific OA models is necessary, even considering the main purpose of these models, i.e., translatability to human OA.Entities:
Keywords: Dunkin Hartley; guinea pigs; in vivo models; spontaneous osteoarthritis; treatments
Mesh:
Year: 2022 PMID: 35806306 PMCID: PMC9266929 DOI: 10.3390/ijms23137309
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Systematic review flow diagram. The PRISMA flow diagram for the systematic review detailing the database searches, the number of abstracts screened, and the full texts retrieved.
Preclinical in vivo studies evaluating naturally occurring OA in guinea pigs.
| ANIMALS (Age) | AIM | EVALUATIONS | RESULTS | REF. |
|---|---|---|---|---|
| 21 female DH guinea pigs (3, 5 and 9 mo) | To describe the age dependent cartilage degeneration in OA progression | MRI | At 9 mo ↓ stain intensity, CT; ↑ cartilage degeneration | [ |
| 12 female DH guinea pigs (6.5, 8, 9.5 and 11 mo) | To describe structural features of OA and the progressive changes during aging | Micro-CT | Continuous OA changes gradually occur from 9.5 mo. | [ |
| 60 female DH guinea pigs (8, 10 and 12 mo) | To observe chondrocyte and matrix degradation in the superficial surface cartilage during aging | Histology/histomorphometry | At 10 mo ↑ surface hyperthrophic chondrocytes, COLLX, MMP13, Caspase3. | [ |
| 30 male DH guinea pigs (2, 3, 5, 9 and 15 mo) | To evaluate joint changes in spontaneous OA | Micro-CT | At 2 and 3 mo mild articular surface irregularities, slight ↓ PG. | [ |
| 40 male DH guinea pigs (1, 3, 6 and 9 mo) | To investigate the association between changes in SB and sGAG content of articular cartilage in spontaneous OA | Micro-CT | At 3 mo ↓ chondrocytes. | [ |
| 24 male DH guinea pigs (2, 3, 5 and 7 mo) | To evaluate changes in the quadriceps skeletal muscle in spontaneous OA | Histology/histomorphometry | At 2 mo free from OA. | [ |
| 18 male DH guinea pigs (2.5, 5 and 7.5 mo) | To determine structural changes and OPG/RANKL during development of OA | Micro-CT | During ageing ↑ SBT, OPG, cartilage fibrillation, PG loss, OARSI score; ↓ RANKL, cartilage cellularity | [ |
| 60 male DH guinea pigs (1, 3, 5, 7 and 9 mo) | To study the progression of spontaneous OA | Histology/histomorphometry | During ageing ↑ OARSI score, instantaneous modulus; ↓ CT | [ |
| 10 male DH guinea pigs (21.2 ± 2.9 mo) | To characterize association between SB circulation and bone structure and cartilage degeneration in spontaneous OA | Macroscopy | Mild OA than severe OA, no intraosseous thrombi | [ |
| 66 male and 66 female DH guinea pigs (1–11 mo) | To investigate the structural alterations in spontaneous OA | Micro-CT | From 5 mo ↑ degeneration of the articular cartilage. | [ |
| 18 DH and 18 BS2 guinea pigs (1, 2 and 3 mo) | To investigate the spatial and temporal SB change of spontaneous OA at early stage | Micro-CT | DH ↑ SB BMD, SBT, BMD, BV/TV, Osterix positive cells, TbTh; ↓ porosity, SMI, TbPf, TbSp, DA than BS2 | [ |
| 21 female DH and 21 female BS2 guinea pigs (1, 2 and 3 mo) | To evaluate dynamic changes in the rod-and-plate microstructure | Micro-CT | DH ↑ BV/TV than BS2. | [ |
| 24 male DH and 24 male BS2 guinea pigs (10 wks and 4, 6 and 7.5 mo) | To determine the role of chondrocyte apoptosis in spontaneous OA | Histology/histomorphometry | DH ↑ OARSI score, fibrillation, PG loss, apoptotic cells than BS2. | [ |
| 24 male DH and 24 male BS2 guinea pigs (10 wks and 4, 6 and 7.5 mo) | To investigate the association between bone remodeling and cartilage degradation with chondrocyte apoptosis in spontaneous OA | Micro-CT | DH ↑ TbTh, TbN, BMD, BV/TV, cartilage degradation; ↓ TbSp than BS2. | [ |
| 24 male DH and 24 BS2 guinea pigs (10 wks and 4, 6 and 7.5 mo) | To investigate the temporal and the spatial relationship between bone remodeling in Sbp and Tb in spontaneous OA | Micro-CT | DH ↓ GpTh during aging. | [ |
| 10 male and female DH and 10 male and female Strain 13 guinea pigs (12 mo) | To determine the association of cartilage degeneration with subchondral BMD in spontaneous OA | Macroscopy | DH male and Strain 13 female ↑ severe cartilage degeneration, surface fibrillation, cartilage clefts, PG loss, Mankin score, BMD than DH female and Strain 13 male | [ |
| 18 male DH and 18 male Strain 13 guinea pigs (5, 9 and 15 mo) | To evaluate skeletal muscle dysfunction, articular cartilage degeneration, and bone loss during aging in spontaneous OA | MRI | DH ↑ OARSI, gastrocnemius and soleus mass; ↓ fiber angle than Strain 13. | [ |
| 40 female DH guinea pigs (1, 3, 6, 9 and 12 mo) | To evaluate age-related changes in articular cartilage, BMD, and estradiol levels | ELISA of serum | At 3 mo mild ulceration, focal PG loss and fibrillation, formation of microcilia. | [ |
| 32 female DH guinea pigs (3, 6, 9 and 12 mo) | To evaluate TGF-β activity in OA progression | Micro-CT | At 3 mo superficial zone undulation with matrix loss, pSmad2/3 in all zones. | [ |
| 20 male DH guinea pigs (2, 4, 8 and 12 mo) | To evaluate the expression of PPARγ, and H- and L-PGDS during spontaneous OA | Histology/histomorphometry | At 4 mo minor surface irregularity, initial Safranin O decrease. | [ |
| 16 male DH guinea pigs (6 and 12 mo) | To determine the association between cartilage IGF-1 with loss of chondrocyte and ECM breakdown in spontaneous OA | Histology/histomorphometry | During ageing ↓ cellularity, matrix integrity, IGF-1; ↑ cartilage disruption, PG loss, Mankin score | [ |
| 25 male DH guinea pigs (1, 3, 6, 9 and 12 mo) | To investigate the expression of MGP in spontaneous OA | Proteomics analysis | During ageing ↑ Mankin score, MGP than 1, 3, 6, 9 mo | [ |
↑ = increase; ↓= decrease.
Figure 2(A) Medial tibial plateau and (B) medial articular compartment of DH guinea pigs at 12 months of age. Surface irregularities and loss of staining in the superficial and medial cartilage surfaces are visible. (C) Medial tibial plateau and (D) medial articular compartment of DH guinea pigs at 21 months of age. High fibrillation, reduced staining, and cartilage thickness are observed. SB: subchondral bone, EB: epiphyseal bone, T: medial tibial plateau, F: medial femoral condyle, M: meniscus, H: Hypocellularity zone; C: clusters; FC: femoral condyle, MTP: medial tibial plateau. Toluidine blue/Fast Green staining. (A,C) 50× of magnification; (B,D) 8× of magnification.
Preclinical in vivo studies evaluating treatments in naturally occurring OA in DH guinea pigs.
| ANIMALS (Age) | TREATMENTS | EVALUATIONS | RESULTS | REF. |
|---|---|---|---|---|
| INJECTIVE TREATMENTS | ||||
| 24 female DH guinea pigs (3 and 6 mo) | i.a. injections of PBS or EGCG 1/wk for 3 mo | Endurance test | EGCG ↑ running endurance, COLL II; ↓ roughness, ulceration, osteophyte, OARSI score, surface erosion, PG and GAG loss, MMP13, p16Ink4a. | [ |
| 24 male DH guinea pigs (3 and 6 mo) | i.a. injections of saline solution or PRP 1/wk for 3 times | ELISA | PRP ↓ COMP, OARSI score, synovitis score, synovial vascularity | [ |
| 32 DH guinea pigs (8 and 11 mo) | 1 or 3 (1/wk) i.a. injections of PRP | Histology/histomorphometry | At 8 mo: | [ |
| 42 DH guinea pigs (3 and 11 mo) | i.a. injections of HA ± CCL25 (63, 693 or 6993 pg) 1/wk for 5 mo | Histology/histomorphometry | HA + CCL25 (693 and 6993 pg) ↓ OARSI score than HA alone | [ |
| 60 male DH guinea pigs (7 mo) | i.a. injections of PBS, HA, PBS + hMSCs or HA + hMSCs | Macroscopy | HA weak matrix staining and cell depletion. | [ |
| 9 DH strain 051 guinea pigs | i.a. injection of Pa-MSCs or Re-MSCs | ELISA | Re-MSCs ↓ TNFα, RANTES, OARSI score. | [ |
| 6 male DH guinea pigs | i.a. injections of TV and PBS or TV and NTV for 2 mo | RT-PCR | TV ↓ IL1β expression than PBS and NTC | [ |
| 32 male DH guinea pigs | i.a. injections of TV and NTV, Ad-Luc and Ad-hIRAP or TV and PBS for 2 or 4 mo | Histology/histomorphometry | TV and Ad-hIRAP ↓ TNFα, IL8, INFy, IL1β expression; ↑ TGFβ1 than NTV and Ad-Luc. | [ |
| 50 female SPF-grade DH albino guinea pigs (9, 10 and 11 mo) | i.a. injections of rapa, saline or 3-MA | Histology/histomorphometry | 3-MA ↑ OARSI score, MMP13, Glycogenin 1, Caspase3, Tunel; ↓ Aggrecan, Beclin 1. | [ |
| 27 male DH guinea pigs | i.a. injections of PTH (1–34) for 3 mo | Micro-CT | PTH (1–34) ↑ GAG; ↓ OARSI score, apoptosis rate | [ |
| 48 female DH guinea pigs (1 and 3 mo) | s.c. injections of saline solution or PTH for 3 or 6 mo | Histology/histomorphometry | During aging ↑ MMP13, SOST; ↓ COLL II. | [ |
| 16 male DH guinea pigs (3.5 mo) | s.c injection of sodium lactate solution or DFO for 7.5 mo | CBC | DFO ↑ OARSI score, mTOR, NF-κB p65, PTGS-2, BAD, BAX, BAK, Caspase-9, Caspase-3, COLL II, ACAN, MMP2, MMP9, MMP13; ↓ 4-HNE, p-AMPKα, TIMP2, change in distance traveled, change in average speed | [ |
| 48 male DH guinea pigs (1.5 and 3 mo) | s.c. injections of risedronate for 1.5, 3 or 6 mo | Macroscopy | Risedronate ↓ OS/BS, BFR/BS, Sb.Th, serum CTX-II, MS/BS | [ |
|
| ||||
| 27 male DH guinea pigs | Rapa ± metformin for 3 mo | Micro-CT | Rapa ± metformin ↑ OARSI score, PG loss, cortical th; ↓ P-RPS6. | [ |
| 24 male DH guinea pigs | Calorie-restricted, HFD or calorie-restricted HFD for 3 mo | Micro-CT | Regular chow ↑ surface fibrillation, fissures. | [ |
| 65 DH guinea pigs | Oleuropein, Rutin or Rutin + curcumin for 8 mo | ELISA | Oleuropein, Rutin or Rutin + curcumin ↓ OARSI score, synovial score, serum PGE2, Fib3-1 and Fib3-2, Coll2-1NO2 kinetic curve, cellularity; ↑ surface integrity, PG during aging. | [ |
| 21 DH giunea pigs (3, 6 and 12 mo) | CM-01 until 6, 12 or 18 mo | Radiograph | CM-01 ↓ meniscal calcification, osteophytes, surface lesions, PG and chondrocyte loss, cartilage degeneration, Mankin score, MMP13; ↑ cartilage bars in SB, CT | [ |
| 50 female DH guinea pigs (3 wks, 1 and 8 mo) | D-GlcN or CS Na until 8, 12 or 18 mo | Histology/histomorphometry | D-GlcN and CS Na ↓ Mankin score, MMP3; ↑ total RNA, chondrocytes. | [ |
|
| ||||
| 18 male DH guinea pigs (3 and 17 mo) | EA for 1 mo | Nociceptive Behavioral Test | EA ↑ mechanical withdraw threshold; ↓ fibrillation, NLRP3, Caspase-1 and IL1β, serum TNFα and IL1β, cartilage MMP13 | [ |
| 10 male DH guinea pigs | EA for 3 wks | Open-field enclosure monitoring parameters | EA ↑ average speed, maximum speed, total distance traveled, stride length, COLL II, FGF18, TGFβ1, TIMP1, SOD2 | [ |
| 25 female DH guinea pigs (5, 9 and 18 mo) | Hyperthermia | Histology/histomorphometry | Hyperthermia ↑ HSP70; ↓ Mankin score, ULK1, Beclin1 positive cells | [ |
| 15 DH guinea pigs | PEMFs at 37 or 75 Hz for 3 mo | Histology/histomorphometry | PEMFs at 37 and 75 Hz ↓ cartilage degeneration, Mankin score, FI, SBT, TbN; ↑ TbTh, TbSp. | [ |
| 56 DH guinea pigs | Pure rapa ± LIPUS, L-rapa ± LIPUS, or LIPUS for 2 mo | Histology/histomorphometry | L-rapa ± LIPUS ↑ GAG, cartilage COLL II; ↓ OARSI score, cartilage MMP13. | [ |
|
| ||||
| 86 male DH guinea pigs | A subcutaneous mini-osmotic pump filled with TN14003, T140 or AMD3100 for 3 mo | ELISA | TN14003 ↓ serum SDF1, MMP3, MMP9, MMP13; ↑ COLL II, ACAN. | [ |
| 36 male DH guinea pigs | A subcutaneous mini-osmotic pump filled with T140 or PBS for 3 mo | ELISA | T140 ↓ serum SDF1, OA changes and severity, Mankin score, cartilage damage, MMP3, MMP9, MMP13 expression, serum SDF1; ↑ COLL II, ACAN expression, COLL II protein | [ |
| 35 male DH guinea pigs | A subcutaneous mini-osmotic pump filled with AMD3100 or PBS for 3 mo | ELISA | PBS deep and wide fissures. | [ |
|
| ||||
| 36 male DH guinea pigs | Physical activity on a flatbed treadmill at a rate of 20–25 m/min, 5 days/wk for 22 wks | Histology/histomorphometry | Physical activity ↑ Aggrecan; ↓ depth of cartilage degeneration | [ |
↑ = increase; ↓= decrease; AMPK = AMP-activated protein kinase; ARGS = aggrecan neoepitopes; AST = aspartate aminotransferase; BAD = BCL-2-associated death promoter; BAK = BCL-2 homologous antagonist killer; BAX = BCL-2-associated x protein; BFR/BF = bone formation rate; BMD = bone mineral density; BS2 = Bristol Strain-2s; BUN = blood urea nitrogen; BV/TV = bone volume/tissue volume; C2C = type II collagen cleavage; CBC = Complete Blood Count; CCL25 = MSC-recruiting chemokine C-C motif ligand 25; CM-01 = Carolinas Molecule-01; COLL = collagen; COMP = cartilage oligomeric matrix protein; CS Na = chondroitin sulfate Sodium; CT = Cartilage thickness; CTV/TV = calcified tissue volume fraction; CTX-II: C-terminal telopeptide of type II collagen; DFO = deferoxamine; D-GlcN = D glucosamine; DH = Dunkin-Hartley; DMMB = dimethylmethylene blue dye; DXA = Dual-energy X-ray absorptiometry; EA = electroacupuncture; EGCG = Epigallocatechin 3-gallate; FI = fibrillation index; Fib3 = Fibulin 3 fragments; FGF18 = fibroblast growth factor 18; FMT = fluorescence molecular tomography; FTH = Ferritin heavy chain; GAG = glycosaminoglycans; H&E = Hematoxylin and Eosin; HA = Hyaluronic Acid; HAMP = hepcidin; HDF = High Fat Diet; hMSCs = human mesenchymal stem cells; HSP70 = heat shock protein 70; IHC = immunohistochemistry; IL = Interleukin; INF = Interferon; IRAP = IL-1 receptor antagonist protein; LIPUS = Low-intensity pulsed ultrasound; MAR = mineral appositional rate; MCP1 = monocyte chemoattractant protein-1; MGP = Matrix Gla (γ-carboxyglutamate) protein; MMA = methylmetacrilate; MMP = metalloproteinase; mo = months; MS/BS = mineralizing surfaces; mTOR = mammalian target of rapamycin; NF-κB p65 = nuclear factor kappa B p65; NLRP3 = nucleotide-binding and oligomerization domain-like receptor containing protein 3; NRF2 = nuclear factor erythroid-2-related factor 2; NTC = non-targeting vector control; NTV = non-targeting control vector; OCT = optimal cutting temperature; OPG = Osteoprotegerin; OS/BS = osteoid-covered surfaces; Pa-MSCs = MSCs isolated from the synovial fluid of OA patients; PBS = phosphate buffered solution; PCNA = proliferating cell nuclear antigen; PEMFs = pulsed electromagnetic fields; PG = Proteoglycans; PGE2 Prostaglandin E2; PRDX1 = peroxiredoxin 1; PRP = Platelet Rich Plasma; PTGS-2 = prostaglandin-endoperoxide synthase 2; PTH (1–34) = parathyroid hormone; PTH1R = PTH receptor; RANTES = regulated on activation, normal T cell expressed and secreted; RANKL = receptor activator of nuclear factor-kB ligand; Rapa = rapamycin; RBC = red blood cells; Re-MSCs = Reprogrammed MSCs; RPS6 = Ribosomal protein S6; SB = Subchondral bone; Sb.St = subchondral bone strength; Sb.Th = subchondral bone thickness; SBT = Subchondral bone thickness; SDF1 = stromal cell derived factor-1; SF = Synovial Fluid; SLC11A2/DMT1 = Divalent metal transporter 1; SLC39A14/ZIP14 = ZRT/IRT-like protein 14; SLC40A1/FPN = Ferroportin; SMI = Structure Model Index; SOD = superoxide dismutase; SOST = sclerostin; SPF = specific pathogen-free; TbSp = Trabecular separation; TbTh = Trabecular Thickness; TFR1 = Transferrin receptor 1; TGFβ1 = Transforming Growth Factor β1; TIMP = tissue inhibitor of metalloproteinases; TNF = Tumor Necrosis Factor; TUNEL = terminal deoxynucleotide transferase-mediated dUTP nick end labeling; TV = targeting knockdown IL1β vector; ULK1 = Unc-51-like kinase 1; WB = Western Blot; WBC = white blood cells; wk = week.
Figure 3(A,B) Medial articular compartment of a DH guinea pigs of 21 months of age. High fibrillation, reduced staining and cartilage thickness are observed. (C,D) Madial articular compartment of a DH guinea pigs of 21 months of age treated with PEMFs at 75 Hz. An increased cartilage preservation is much more evident and reduced fibrillation, increased PG content and normal cell distribution are observed. FC: femoral condyle, MTP: medial tibial plateau, H: Hypocellularity zone, C: clusters, F: fibrillation zone. Toluidine blue/Fast green staining. (A,C) 8× of magnification; (B,D) 50× of magnification.
Risk of bias of in vivo studies.
| Ref. | Sequence Generation | Baseline Characteristics | Allocation Concealment | Random Housing | Blinding | Random Outcome Assessment | Blinding | Incomplete Outcome Data | Selective Outcome Reporting | Other Sources of Bias |
|---|---|---|---|---|---|---|---|---|---|---|
| [ | NO | YES | NO | NO | NO | YES | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | YES | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | YES | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | YES | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | YES | YES | YES | UNCLEAR |
| [ | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| [ | YES | YES | NO | NO | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | YES | YES | NO | YES | NO | YES | NO | YES | YES | YES |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | UNCLEAR | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | YES | YES | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | YES | YES | YES | YES | YES |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | YES | NO | YES | YES | YES | YES |
| [ | YES | YES | YES | YES | NO | YES | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | YES | YES | YES | YES | NO | YES | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | YES | NO | YES | YES | UNCLEAR |
| [ | YES | YES | YES | YES | NO | YES | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | YES | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | YES | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | YES | YES | YES | YES | NO | YES | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | YES | YES | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | NO | NO | YES | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | YES | YES | NO | YES | YES | YES | YES | UNCLEAR |
|
| NO | YES | NO | NO | NO | NO | NO | YES | YES | UNCLEAR |
|
| NO | YES | NO | YES | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | YES | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | YES | NO | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
| [ | NO | YES | NO | YES | NO | NO | YES | YES | YES | UNCLEAR |
Sequence generation: Was the allocation sequence adequately generated and applied?; Baseline characteristics: Were the groups similar at baseline or were they adjusted for confounders in the analysis? Allocation concealment: Was the allocation to the different groups adequately concealed during? Random housing: Were the animals randomly housed during the experiment? Blinding: Were the caregivers and/or investigators blinded from knowledge of which intervention each animal received during the experiment? Random outcome assessment: Were animals selected at random for outcome assessment? Blinding: Was the outcome assessor blinded? Incomplete outcome data: Were incomplete outcome data adequately addressed? Selective outcome reporting: Are reports of the study free of selective outcome reporting? Other sources of bias: Was the study apparently free of other problems that could result in high risk of bias? “Yes” indicates low risk of bias; “no” indicates high risk of bias; and “unclear” indicates an unclear risk of bias. If one of the relevant signaling questions is answered with “no,” this indicates high risk of bias for that specific entry.
Quality assessment of in vivo studies.
| Ref. | TITLE | ABSTRACT | INTRODUCTION | METHODS | RESULTS | DISCUSSION | TOTAL |
|---|---|---|---|---|---|---|---|
| [ | 1 | 2 | 3 | 13 | 6 | 5 |
|
| [ | 0 | 2 | 2 | 12 | 2 | 1 |
|
| [ | 1 | 1 | 1 | 11 | 2 | 4 |
|
| [ | 1 | 2 | 3 | 7 | 2 | 2 |
|
| [ | 1 | 2 | 2 | 15 | 4 | 5 |
|
| [ | 1 | 2 | 3 | 10 | 2 | 5 |
|
| [ | 1 | 2 | 3 | 12 | 2 | 3 |
|
| [ | 1 | 2 | 2 | 8 | 2 | 3 |
|
| [ | 1 | 2 | 3 | 12 | 5 | 3 |
|
| [ | 1 | 2 | 3 | 8 | 2 | 5 |
|
| [ | 1 | 2 | 2 | 11 | 2 | 2 |
|
| [ | 1 | 2 | 1 | 11 | 2 | 5 |
|
| [ | 1 | 2 | 3 | 16 | 7 | 5 |
|
| [ | 1 | 2 | 3 | 11 | 6 | 4 |
|
| [ | 1 | 2 | 1 | 8 | 3 | 1 |
|
| [ | 1 | 2 | 3 | 13 | 2 | 2 |
|
| [ | 1 | 2 | 2 | 9 | 1 | 3 |
|
| [ | 1 | 2 | 2 | 9 | 2 | 3 |
|
| [ | 1 | 2 | 3 | 12 | 2 | 1 |
|
| [ | 1 | 2 | 2 | 11 | 2 | 1 |
|
| [ | 1 | 2 | 2 | 11 | 2 | 1 |
|
| [ | 1 | 2 | 3 | 13 | 2 | 5 |
|
| [ | 1 | 2 | 3 | 14 | 2 | 3 |
|
| [ | 1 | 2 | 2 | 10 | 2 | 5 |
|
| [ | 1 | 2 | 3 | 10 | 3 | 1 |
|
| [ | 1 | 2 | 2 | 12 | 1 | 3 |
|
| [ | 1 | 2 | 3 | 12 | 1 | 3 |
|
| [ | 1 | 2 | 3 | 11 | 5 | 4 |
|
| [ | 1 | 2 | 2 | 10 | 1 | 2 |
|
| [ | 1 | 2 | 2 | 9 | 2 | 2 |
|
| [ | 1 | 2 | 3 | 13 | 3 | 4 |
|
| [ | 1 | 2 | 3 | 12 | 2 | 4 |
|
| [ | 1 | 2 | 3 | 13 | 5 | 3 |
|
| [ | 1 | 2 | 3 | 16 | 6 | 4 |
|
| [ | 1 | 2 | 3 | 12 | 7 | 4 |
|
| [ | 0 | 2 | 3 | 16 | 3 | 4 |
|
| [ | 1 | 2 | 3 | 13 | 4 | 3 |
|
| [ | 1 | 2 | 2 | 14 | 5 | 5 |
|
| [ | 1 | 2 | 2 | 12 | 2 | 3 |
|
| [ | 0 | 1 | 2 | 8 | 2 | 1 |
|
| [ | 1 | 2 | 2 | 12 | 2 | 3 |
|
| [ | 1 | 2 | 3 | 16 | 6 | 3 |
|
| [ | 1 | 2 | 2 | 11 | 3 | 3 |
|
| [ | 1 | 2 | 2 | 13 | 3 | 3 |
|
| [ | 0 | 2 | 3 | 13 | 4 | 2 |
|
| [ | 0 | 2 | 2 | 13 | 2 | 2 |
|
| [ | 0 | 2 | 2 | 13 | 2 | 2 |
|
| [ | 0 | 2 | 2 | 12 | 3 | 2 |
|
| [ | 1 | 2 | 3 | 12 | 2 | 1 |
|